Response to ASX Query Letters
Released
Released
Announcement PDF
Market Announcement
4 August 2025
Attached for the information of the market are ASX’s query letters to Alterity Therapeutics Limited (ASX:ATH)
dated 24 July 2025 and 30 July 2025 and ATH’s responses 28 July 2025 and 3 August 2025.
4 August 2025
ASX Limited
#10943519v1
Market Announcement 1/1
ASX Customer Service Centre 131 279 | asx.com.au
24 July 2025
Reference: ODIN111104
Ms Abby Macnish
Company Secretary
Alterity Therapeutics Limited
Suite 4, Level 14, 350 Collins Street
Melbourne, Vic 3000
By email: amacnish@alteritytx.com
Dear Ms Macnish
Alterity Therapeutics Limited (‘ATH’): ASX Aware Letter
ASX refers to the following:
A. ATH’s announcement titled ‘Alterity Therapeutics Announces Publication on Novel MRI Endpoint from the
bioMUSE Natural History Study’ (the ‘Announcement’) released on the ASX Market Announcements Platform
(‘MAP’) at 10:08 AM on 24 July 2025 disclosing that a neuroimaging measure developed in ATH’s Biomarkers
of Progression in Multiple System Atrophy (bioMUSE) Natural History Study was featured in the peerreviewed journal Annals of Clinical and Translational Neurology (the ‘Information’). The publication being
entitled ‘The MSA Atrophy Index (MSA-AI): An Imaging Marker for Diagnosis and Clinical Progression in
Multiple System Atrophy’ (the ‘Article’). The Announcement was indicated to be market-sensitive by ATH
when it was submitted to MAP.
B. The Wiley Online Library Website, which discloses that the Article was first published on 14 July 20251.
C. ASX’s letter dated 11 July 2025 (‘Price Query Letter’) and ATH’s letter in response dated 14 July 2025 (‘Price
Query Response’). Both the Price Query Letter and Price Query Response were released together on MAP
on 14 July 2025. In the Price Query Response in response to question 1, ATH stated it was not aware of any
information concerning it that had not been announced to the market which, if known, could explain recent
trading in its securities. ASX notes that ATH’s answer to question 3 in the Price Query Response does not
make mention of the Article.
D. The change in the price of ATH’s securities from a low of $0.013 immediately prior to the release of the
Announcement to a high of $0.015 at close of trade on 24 July 2025 following the release of the
Announcement.
E. Listing Rule 3.1, which requires a listed entity to immediately give ASX any information concerning it that a
reasonable person would expect to have a material effect on the price or value of the entity’s securities.
F. The definition of “aware” in Chapter 19 of the Listing Rules, which states that:
“an entity becomes aware of information if, and as soon as, an officer of the entity (or, in the case of a
trust, an officer of the responsible entity) has, or ought reasonably to have, come into possession of the
information in the course of the performance of their duties as an officer of that entity.”
G. Section 4.4 in Guidance Note 8 Continuous Disclosure: Listing Rules 3.1 – 3.1B titled “When does an entity
become aware of information?”
H. Listing Rule 3.1A, which sets out exceptions from the requirement to make immediate disclosure as follows.
1
https://onlinelibrary.wiley.com/doi/10.1002/acn3.70106
ASX Limited [[Listings]]
#10938532v1
ASX Customer Service Centre 131 279 | asx.com.au
“3.1A
Listing rule 3.1 does not apply to particular information while each of the following is satisfied
in relation to the information:
3.1A.1 One or more of the following 5 situations applies:
x
It would be a breach of a law to disclose the information;
x
The information concerns an incomplete proposal or negotiation;
x
The information comprises matters of supposition or is insufficiently definite
to warrant disclosure;
x
The information is generated for the internal management purposes of the
entity; or
x
The information is a trade secret; and
3.1A.2 The information is confidential and ASX has not formed the view that the information
has ceased to be confidential; and
3.1A.3 A reasonable person would not expect the information to be disclosed.”
I.
Section 14 of Guidance Note 14 ASX Market Announcements Platform which states (relevantly):
“MAP should only be used to publish information that is appropriately given to ASX under the Listing Rules or
the Corporations Act for publication to the market. It should not be used as a guise to publish material that
is really promotional, political or tendentious in nature.”
J.
The concept of “confidentiality” detailed in section 5.8 of Guidance Note 8 Continuous Disclosure: Listing
Rules 3.1 – 3.1B. In particular, the Guidance Note states that:
“Whether information has the quality of being confidential is a question of fact, not one of the intention
or desire of the entity. Accordingly, even though an entity may consider information to be confidential
and its disclosure to be a breach of confidence, if it is in fact disclosed by those who know it, then it is no
longer a secret and it ceases to be confidential information for the purposes of this rule.”
Request for information
Having regard to the above, ASX asks ATH to respond separately to each of the following questions:
1. Does ATH consider the Information, or any part thereof, to be information that a reasonable person would
expect to have a material effect on the price or value of its securities?
2. If the answer to question 1 is “no”, please:
2.1
advise the basis for that view;
2.2
explain why ATH indicated the Announcement to be market-sensitive when it was lodged on MAP; and
2.3
explain the Listing Rule or Corporations Act basis necessitating the publication of the Announcement
on MAP.
3. When did ATH first become aware of the Information referred to in question 1 above?
4. If ATH first became aware of the Information referred to in question 1 before the date of the Announcement,
did ATH make any announcement prior to that date which disclosed the Information? If not, please explain
why the Information was not released to the market at an earlier time, commenting specifically on when you
believe ATH was obliged to release the Information under Listing Rules 3.1 and 3.1A and what steps ATH took
to ensure that the Information was released promptly and without delay.
2/3
ASX Customer Service Centre 131 279 | asx.com.au
#10938532v1
Please answer separately for each of the items in question 1 above and provide details of the prior
announcement if applicable.
5. Please provide a chronology of the peer review process referred to in the Announcement. This chronology
should include (at minimum) details around when the relevant information was submitted to be peer
reviewed and when ATH was first advised of the outcome of the peer review.
6. Please confirm that ATH is in compliance with the Listing Rules and, in particular, Listing Rule 3.1.
7. Please confirm that ATH’s responses to the questions above have been authorised and approved in
accordance with its published continuous disclosure policy or otherwise by its board or an officer of ATH with
delegated authority from the board to respond to ASX on disclosure matters.
When and where to send your response
This request is made under Listing Rule 18.7. Your response is required as soon as reasonably possible and, in
any event, by no later than 9:30 AM AEST Wednesday, 30 July 2025.
You should note that if the information requested by this letter is information required to be given to ASX under
Listing Rule 3.1 and it does not fall within the exceptions mentioned in Listing Rule 3.1A, ATH’s obligation is to
disclose the information ‘immediately’. This may require the information to be disclosed before the deadline set
out above and may require ATH to request a trading halt immediately if trading in ATH’s securities is not already
halted or suspended.
Your response should be sent by e-mail to ListingsComplianceMelbourne@asx.com.au. It should not be sent
directly to the ASX Market Announcements Office. This is to allow us to review your response to confirm that it
is in a form appropriate for release to the market, before it is published on the ASX Market Announcements
Platform.
Suspension
If you are unable to respond to this letter by the time specified above, ASX will likely suspend trading in ATH’s
securities under Listing Rule 17.3.
Listing Rules 3.1 and 3.1A
In responding to this letter, you should have regard to ATH’s obligations under Listing Rules 3.1 and 3.1A and
also to Guidance Note 8 Continuous Disclosure: Listing Rules 3.1 – 3.1B. It should be noted that ATH’s obligation
to disclose information under Listing Rule 3.1 is not confined to, nor is it necessarily satisfied by, answering the
questions set out in this letter.
Release of correspondence between ASX and entity
We reserve the right to release all or any part of this letter, your reply and any other related correspondence
between us to the market under Listing Rule 18.7A. The usual course is for the correspondence to be released to
the market.
Regards
ASX Compliance
3/3
ASX Customer Service Centre 131 279 | asx.com.au
#10938532v1
30 July 2025
Reference: ODIN111263
Ms Abby Macnish
Company Secretary
Alterity Therapeutics Limited
Suite 4, Level 14, 350 Collins Street
Melbourne, Vic 3000
By email: amacnish@alteritytx.com
Dear Ms Macnish
Alterity Therapeutics Limited(‘ATH’): Further query letter
ASX refers to the following:
A. ATH’s response dated 28 July 2025 (the ‘ATH Response’) to ASX’s query letter dated 24 July 2025 (the ‘ASX
Letter’). Capitalised terms in this letter have the same meaning as those defined in the ASX Letter and the
ATH Response. The ATH response stated (relevantly):
i.
“ATH does not consider the information contained in the ASX ‘Announcement’ released to the
Market on 24th July 2025 to be information that a reasonable person would expect to have a
material effect on the price or value of its securities.
The Company made an isolated error in designating the ‘Announcement’ market sensitive. Despite
this error being a one-off occurrence, the Company is promptly taking action to review all internal
governance processes. See also response to question 2 (b) below.”
ii.
“The information outlined in the ASX announcement regarding ATH’s MSA-AI Technology on 24 July
2025 had previously been disclosed to the market on two previous occasions:
the Company’s Oral Presentation on MSA-AI was released to ASX on 7 May 2025 AET under
the title ‘Alterity Therapeutics Announces Multiple Oral and Poster Presentations to be
Featured at the International MSA Congress’ (and was presented on 11 May 2025 AET at
the International MSA Congress); and
the MSA-AI data presented by the Company at the 35th International Symposium on the
Autonomic Nervous System was released to ASX on 12 November 2024 AET under the title
‘Alterity Therapeutics Announces Presentation on Tracking the Progression of Multiple
System Atrophy at International Symposium’.
Given that the publication presented similar data to what had previously been disclosed to the
market, we did not consider that a reasonable person would expect this release to have a material
effect on the price or value of our securities. Moreover, while the presentations and publications
described novel methods to diagnose and track Multiple System Atrophy but did not include any
data regarding a therapy being developed by the Company.”
iii. “(Lodging the Announcement on MAP as market-sensitive) was an error made by the company that
arose from a miscommunication between two internal stakeholders.
The Company is promptly actioning a review of all internal governance processes to ensure this
miscommunication does not happen again.”
ASX Limited [[Listings]]
#10940709v2
ASX Customer Service Centre 131 279 | asx.com.au
iv. “The company received email notification of the publication in the Annals of Clinical and
Translational Neurology on 15th July 2025 at 4:40pm AEST. The Price Query was received on 11th
July 2025 with the company response dated 14th July 2025.”
v.
“ATH did not make any announcement regarding the publication prior to disclosure on 24 July 2025.
As noted above, the information was not released earlier because the Company determined that the
disclosure was not materially price sensitive.”
B. ATH’s announcement titled ‘Alterity to Deliver Oral Presentation of ATH434 Trial at AAN’, released on the
ASX Market Announcements Platform (‘MAP’) on 3 April 2025 which disclosed that ATH would deliver a
poster presentation to the American Academy of Neurology (‘AAN’) on 5 April 2025, and an oral presentation
to AAN on 9 April 2025.
C. ATH’s announcement titled ‘Notice Under Section 708A’, released on MAP on 7 April 2025 (the ‘Cleansing
Notice’) which stated (relevantly):
“as at the date of this notice there is no information to be disclosed which is ‘excluded information’ (as defined
in sections 708A(7) and 708A(8) of the Corporations Act) which is required to be disclosed by the Company.”
D. ATH’s announcement titled ‘Alterity Presents Encouraging New Phase 2 Data in MSA’ (the ‘Phase 2
Announcement’), released on MAP at 10:11AM AEST on 10 April 2025, which disclosed a summary of each
of the poster and oral presentations, including underlying data. ASX notes that ATH submitted this
announcement as ‘market-sensitive’ to ASX Online.
E. ATH’s announcement titled ‘Alterity Phase 2 Presentation at AAN 2025’ (the ‘Phase 2 Presentation’), released
on MAP at 1:59PM AEST on 10 April 2025, which disclosed the presentation slides for the presentation to
AAN. ASX notes that ATH submitted this announcement as ‘market-sensitive’ to ASX Online.
F.
Section 7.10 of Guidance Note 8 titled ‘Ramping announcements’ which states (relevantly):
“ASX is alive to listed entities making market announcements with a view to “ramping up” the price of their
securities. Ramping announcements come in many forms, including:
x
the release of a “business update” or something similar 294, which will typically be worded in an
exuberant fashion but which on closer examination contains little in the way of substance that has
not already been disclosed to the market;”
…
Footnote 294 states: “These types of updates are more appropriately given in a quarterly activities report
under Listing Rule 4.7C rather than in a stand-alone announcement.”
…
“Whenever ASX detects what it suspects to be a ramping announcement, it will give careful consideration to
suspending the entity’s securities from trading and issuing a query letter to the entity asking the entity:
x
if it marked the announcement as market sensitive when it was lodged on MAP, to identify what
information in the announcement the entity considered was market sensitive and why;
x
if it marked the announcement as not being market sensitive when it was lodged on MAP, to explain
its purpose in lodging the announcement on MAP, given its evident view that the information was
not market sensitive and therefore not required to be disclosed under Listing Rule 3.1”
G. Listing Rule 3.1, which requires a listed entity to immediately give ASX any information concerning it that a
reasonable person would expect to have a material effect on the price or value of the entity’s securities.
H. The definition of “aware” in Chapter 19 of the Listing Rules, which states that:
2/5
ASX Customer Service Centre 131 279 | asx.com.au
#10940709v2
“an entity becomes aware of information if, and as soon as, an officer of the entity (or, in the case of a
trust, an officer of the responsible entity) has, or ought reasonably to have, come into possession of the
information in the course of the performance of their duties as an officer of that entity.”
I.
Section 4.4 in Guidance Note 8 Continuous Disclosure: Listing Rules 3.1 – 3.1B titled “When does an entity
become aware of information?”
J.
Listing Rule 3.1A, which sets out exceptions from the requirement to make immediate disclosure as follows.
“3.1A
Listing rule 3.1 does not apply to particular information while each of the following is satisfied
in relation to the information:
3.1A.1
One or more of the following 5 situations applies:
x
It would be a breach of a law to disclose the information;
x
The information concerns an incomplete proposal or negotiation;
x
The information comprises matters of supposition or is insufficiently definite
to warrant disclosure;
x
The information is generated for the internal management purposes of the
entity; or
x
The information is a trade secret; and
3.1A.2
The information is confidential and ASX has not formed the view that the information
has ceased to be confidential; and
3.1A.3
A reasonable person would not expect the information to be disclosed.”
K. The concept of “confidentiality” detailed in section 5.8 of Guidance Note 8 Continuous Disclosure: Listing
Rules 3.1 – 3.1B. In particular, the Guidance Note states that:
“Whether information has the quality of being confidential is a question of fact, not one of the intention or
desire of the entity. Accordingly, even though an entity may consider information to be confidential and its
disclosure to be a breach of confidence, if it is in fact disclosed by those who know it, then it is no longer a
secret and it ceases to be confidential information for the purposes of this rule.”
L.
Listing Rule 15.7 which states:
“An entity must not release information that is for release to the market to any +person until it has given the
information to ASX and has received an acknowledgement that ASX has released the information to the
market.”
Observation
Given the delay between ATH becoming aware of the publication on 15 July 2025 and the release of the
Announcement on MAP on 24 July 2025, to accept ATH’s position that the relevant information was not
information required for release under the Listing Rules, it would appear to ASX that ATH engaged in ramping
conduct.
Request for Information
Having regard to the above, ASX asks ATH to respond separately to each of the following questions:
1. Does ATH consider the contents of the Phase 2 Announcement to be information that a reasonable person
would expect to have a material effect on the price or value of its securities?
2. If the answer to question 1 is “yes”:
3/5
ASX Customer Service Centre 131 279 | asx.com.au
#10940709v2
2.1
Please explain how ATH considers it complied with Listing Rule 3.1 and Listing Rule 15.7 in respect of the
Phase 2 Announcement, given ATH presented the data as early as 5 April 2025 to AAN. In your answer,
please confirm when ATH became aware of the relevant material information.
2.2
Please explain why ATH did not submit the Phase 2 Announcement until after market open on 10 April
2025.
2.3
Does ATH consider the Cleansing Notice to be valid, given it was lodged between ATH presenting to AAN
and the ultimate disclosure of the relevant information on MAP? If so, please explain the basis for that
view. If not, please outline the remedial action ATH intends to take as a result of the invalid cleansing
notice.
3. Does ATH consider the contents of the Phase 2 Presentation to be information that a reasonable person would
expect to have a material effect on the price or value of its securities?
4. If the answer to question 3 is “yes”:
4.1
Please explain the basis for that view, commenting specifically on what new material information was
in the Phase 2 Presentation which was not disclosed in the Phase 2 Announcement, or another
announcement on MAP.
4.2
Please explain why the Phase 2 Presentation was not released on MAP at the same time as the Phase 1
Announcement.
4.3
Please explain how ATH considers it complied with Listing Rule 3.1 and Listing Rule 15.7 in respect of the
information identified by ATH in response to question 4.1 above, ATH presented the data as early as 5
April 2025 to AAN. In your answer, please confirm when ATH became aware of the relevant material
information.
5. If the answer to either question 1 or question 3 is “no”:
5.1
Please explain the basis for ATH’s position in the ATH Response that the erroneous indication of the
Announcement as market-sensitive was an “isolated incident”.
5.2
It would appear to ASX that ATH has engaged in repeated ramping conduct by indicating announcements
to be market-sensitive which, by ATH’s own admission, do not contain any material information for the
purposes of Listing Rule 3.1. If ATH does not consider that it engaged in ramping conduct, please explain
the basis for that view.
6. Please provide further information on the nature of the “error that arose from a miscommunication between
two internal stakeholders” in relation to the Announcement.
7. In light of ATH’s answers to the questions above, please detail the proposed changes ATH intends to make to
its policies and procedures concerning continuous disclosure.
8. Please confirm that ATH is in compliance with the Listing Rules and, in particular, Listing Rule 3.1.
9. Please confirm that ATH’s responses to the questions above have been authorised and approved in
accordance with its published continuous disclosure policy or otherwise by its board or an officer of ATH with
delegated authority from the board to respond to ASX on disclosure matters.
When and where to send your response
This request is made under Listing Rule 18.7. Your response is required as soon as reasonably possible and, in
any event, by no later than 9:30 AM AEST Monday, 4 August 2025.
You should note that if the information requested by this letter is information required to be given to ASX under
Listing Rule 3.1 and it does not fall within the exceptions mentioned in Listing Rule 3.1A, ATH’s obligation is to
4/5
ASX Customer Service Centre 131 279 | asx.com.au
#10940709v2
disclose the information ‘immediately’. This may require the information to be disclosed before the deadline set
out above and may require ATH to request a trading halt immediately if trading in ATH’s securities is not already
halted or suspended.
Your response should be sent by e-mail to ListingsComplianceMelbourne@asx.com.au. It should not be sent
directly to the ASX Market Announcements Office. This is to allow us to review your response to confirm that it
is in a form appropriate for release to the market, before it is published on the ASX Market Announcements
Platform.
Suspension
If you are unable to respond to this letter by the time specified above, ASX will likely suspend trading in ATH’s
securities under Listing Rule 17.3.
Listing Rules 3.1 and 3.1A
In responding to this letter, you should have regard to ATH’s obligations under Listing Rules 3.1 and 3.1A and
also to Guidance Note 8 Continuous Disclosure: Listing Rules 3.1 – 3.1B. It should be noted that ATH’s obligation
to disclose information under Listing Rule 3.1 is not confined to, nor is it necessarily satisfied by, answering the
questions set out in this letter.
Release of correspondence between ASX and entity
We reserve the right to release all or any part of this letter, your reply and any other related correspondence
between us to the market under listing rule 18.7A. The usual course is for the correspondence to be released to
the market.
Yours sincerely
ASX Compliance
5/5
ASX Customer Service Centre 131 279 | asx.com.au
#10940709v2
28 July 2025
By email: melissa.kostopoulos@asx.com.au
Melissa Kostopoulos
Adviser, Listings Compliance (Melbourne) ASX Limited
Dear Melissa
ASX Aware Letter
We refer to your letter dated 24 July 2025 referring to the release to the market by Alterity
Therapeutics Limited (ASX: ATH) (Company) on 24 July 2025 of the Announcement titled “Alterity
Therapeutics Announces Publication on Novel MRI Endpoint from the bioMUSE Natural History
Study’, and the increase in the Company’s share price of $0.002 (from $0.013 immediately prior to
the release and a price of $0.015 at close of trade on that day)
The Company provides the following responses to the ASX’s queries:
ASX Question 1: Does ATH consider the Information, or any part thereof, to be information that a
reasonable person would expect to have a material effect on the price or value of its securities?
No, ATH does not consider the information contained in the ASX ‘Announcement’ released to the
Market on 24th July 2025 to be information that a reasonable person would expect to have a
material effect on the price or value of its securities.
The Company made an isolated error in designating the ‘Announcement’ market sensitive. Despite
this error being a one-off occurrence, the Company is promptly taking action to review all internal
governance processes. See also response to question 2 (b) below.
Your letter noted an increase in the Company’s share price of $0.002 on 24 July 2025, being the
date of the release of the relevant Announcement. Given the level of the Company’s share price,
minor changes can show as significant percentage changes. Similarly, minor changes in volume can
more easily translate into price changes because of the Company’s share price level.
For example, in the period from 25 June 2025 to 25 July 2025 (inclusive), there were 23 trading
days, (and of those, there were 17 days in which there was a share price movement between
opening and close of trading on the relevant day):
Alterity Therapeutics Limited
Suite4, Level 14, 350 Collins Street, Melbourne, VIC 3000 Australia
T: +61 (0)3 9349 4906 | WWW.alteritytherapeutics.com
•
•
•
•
other than days where there was no share price movement between opening and close of
trading on the relevant day, every trading day recorded a price movement greater than 5% (up
or down); and
there was a 7.5% or more movement (up or down) in the Company’s share price on 14 of the 17
days on which there was a share price movement between opening and close of trading on that
day); and
there was a 10% or more movement (up or down) in the Company’s share price on 12 of the 17
days on which there was a share price movement between opening and close of trading on that
day); and
the simple average of the percentage movement in the Company’s share price (up or down) on
those days on which there was a share price movement between opening and close of trading
on that day is 15.76% (which is greater than the percentage change on 24 July 2025).
Similarly, the volume traded on 24 July 2025 was not inconsistent with volumes of the Company’s
shares recently traded, especially in the last few weeks.
Accordingly, recent trading activity shows that the percentage price change on 24 July, and that the
volume of shares traded on that day, is entirely consistent with recent price movements and
trading volumes. Accordingly, we consider that the price movement and volume and on 24 July
2025 supports the Company’s view that the relevant Announcement was not materially price
sensitive.
ASX Question 2: If the answer to question 1 is “no”, please:
a) Advise the basis for that view;
The information outlined in the ASX announcement regarding ATH’s MSA-AI Technology on
24 July 2025 had previously been disclosed to the market on two previous occasions:
-
the Company’s Oral Presentation on MSA-AI was released to ASX on 7 May 2025 AET
under the title ‘Alterity Therapeutics Announces Multiple Oral and Poster Presentations
to be Featured at the International MSA Congress’ (and was presented on 11 May 2025
AET at the International MSA Congress); and
-
the MSA-AI data presented by the Company at the 35th International Symposium on the
Autonomic Nervous System was released to ASX on 12 November 2024 AET under the
title ‘Alterity Therapeutics Announces Presentation on Tracking the Progression of
Multiple System Atrophy at International Symposium’.
Given that the publication presented similar data to what had previously been disclosed to
the market, we did not consider that a reasonable person would expect this release to have
a material effect on the price or value of our securities. Moreover, while the presentations
and publications described novel methods to diagnose and track Multiple System Atrophy
but did not include any data regarding a therapy being developed by the Company.
b) Explain why ATH indicated the Announcement to be market-sensitive when it was lodged
on MAP; and
This was an error made by the company that arose from a miscommunication between two
internal stakeholders.
The Company is promptly actioning a review of all internal governance processes to ensure
this miscommunication does not happen again.
c) Explain the Listing Rule or Corporations Act basis necessitating the publication of the
Announcement on MAP.
Given that the Announcement did not contain information that a reasonable person would
expect to have a material effect on the price or value of its securities, neither the ASX
Listing Rules nor the Corporations Act necessitated the publication of the Announcement
on MAP such that a failure to do so would have been contrary to the requirements of the
ASX Listing Rules or the Corporations Act.
We note that the Announcement was posted on the Company’s website as a press release.
Given the nature of the Company’s operations developing therapies to treat
neurodegenerative disease, the Company considered that, while the information in the
Announcement was not materially price sensitive, the release does nonetheless contribute
to the general knowledge of the progress of the development of the Company’s therapies.
Accordingly, the Company considered it was consistent with good governance to also
publish the press release on the MAP to ensure that any such contribution to the general
knowledge of the progress of the development of the Company’s therapies was available to
all of the market.
ASX Question 3: When did ATH first become aware of the information referred to in question 1
above?
The company received email notification of the publication in the Annals of Clinical and
Translational Neurology on 15th July 2025 at 4:40pm AEST. The Price Query was received on 11th
July 2025 with the company response dated 14th July 2025.
The Company had not received the notice of the publica
Share your feedback
Discover